Имени а. Л. Мясникова фгбу «российский кардиологический научно-производственный комплекс» мз РФ



Скачать 1.22 Mb.
страница5/5
Дата23.04.2016
Размер1.22 Mb.
ТипДиссертация
1   2   3   4   5

IV. Выводы:

  1. Уровень активности Лп-ФЛА2 прямо коррелирует с уровнем ХС, ХС ЛНП, ТГ, мочевой кислоты и обратно с уровнем ХС ЛВП. Уровень массы Лп-ФЛА2 прямо коррелирует с уровнем ХС и ХС ЛНП. Не выявлена связь уровня Лп-ФЛА2 с полом, возрастом, курением, артериальной гипертонией, уровнем Лп(а).

  2. У больных низкой категории риска масса и активность Лп-ФЛА2 ниже, чем у больных более высоких категорий риска. У больных очень высокого, высокого и умеренного риска уровни Лп-ФЛА2 значимо не различаются.

  3. Уровень Лп-ФЛА2 коррелирует с показателями выраженности атеросклероза сонных артерий. Максимальный и суммарный стеноз сонных артерий достоверно больше у лиц с повышенным уровнем Лп-ФЛА2, измеренным по активности, но не по массе.

  4. Имеется корреляция (r=0.4) между уровнем Лп-ФЛА2, измеренным по массе и по активности. С выраженностью атеросклероза сонных артерий в большей степени ассоциируется уровень Лп-ФЛА2, измеренный по активности. Уровни Лп-ФЛА2 по массе и по активности в равной степени ассоциируются с категориями сердечно-сосудистого риска.

  5. У больных, принимающих статины, уровень Лп-ФЛА2, измеренный по массе, ниже, чем у пациентов, не принимающих статины, р<0.001.


V. Практические рекомендации.

Уровень Лп-ФЛА2 измеренный по массе и по активности является фактором риска развития сердечно-сосудистых осложнений и может быть использован в стратификации риска сердечно-сосудистых заболеваний.



При использовании уровня Лп-ФЛА2 в качестве предиктора осложнений или для стратификации риска необходимо исключить пациентов, принимающих статины.

VI. Список литературы

  1. Akosah K.O., Schaper A., Cogbill C., Schoenfeld P. J Am Coll Cardiol. 2003; 41: 1475–1479

  2. Macphee C.H.. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol. 2001;1:121-125

  3. Caslake M.J., Packard C.J., Suckling K.E., et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000; 150:413-419

  4. Dada N., Kim N.W., Wolfert R.L.. Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn. 2002; 2:17-22

  5. Thompson A., Gao P., Orfei L., Watson S., et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies Lancet. 2010 May 1;375(9725):1536-44

  6. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868–874

  7. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685–1695

  8. Zethelius B., Berglund L., Sundstrom J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascularcauses. N Engl J Med 2008;358:2107–2116

  9. Little W.C., Constantinescu M., Applegate R.J., et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988;78:1157–1166

  10. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation 1995;92:657–671.

  11. Fayad ZA. Cardiovascular molecular imaging. Arterioscler Thromb Vasc Biol 2009;29:981–982

  12. Shaw S.Y. Molecular imaging in cardiovascular disease: targets and opportunities. Nat Rev Cardiol 2009;6:569–579

  13. Nahrendorf M., Sosnovik D., French B., et al. Multimodality cardiovascular molecular imaging, part II. Circ Cardiovasc Imaging 2009;2:56–70

  14. Уразалина С.Ж., Семенова А.Е., Сергиенко И.В., с соавт. Субклинический атеросклероз как фактор риска сердечно-сосудистых осложнений. Атеросклероз и дислипидемии, 2012, №2, стр. 13-19

  15. Балахонова Т.В, Трипотень М.И., Погорелова О.А. Ультразвуковые методы оценки толщины комплекса интима-медиа артериальной стенки. Медицинский журнал "SonoAce-Ultrasound" N21, 2010 г

  16. Рогоза А.Н., Балахонова Т.В., Чихладзе Н.М. и др. Современные методы оценки состояния сосудов у больных артериальной гипертонией. Пособие для практикующих врачей. М.: ООО «Издательский дом «Атмосфера», 2008г

  17. Kwee R.M., van Oostenbrugge R.J., Hofstra L., et al. Identifying vulnerable carotid plaques by noninvasive imaging. Neurology. 2008 Jun 10;70(24 Pt 2):2401-9

  18. Brott T.G., Halperin J.L., Abbara S., et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. J Am Coll Cardiol. 2011 Feb 22;57(8):1002-4410

  19. Hulthe J., Wiklund O, Hurt-Camejo E, Bondjers G. Antibodies to Oxidized LDL in Relation to Carotid Atherosclerosis, Cell Adhesion Molecules,and Phospholipase A2. Arterioscler Thromb Vasc Biol. 2001;21:269-274

  20. Gong HP, Du YM, Zhong LN. et al. Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis. Lipids Health Dis. 2011; 10: 13

  21. Mannheim D, Herrmann J, Versari D et al. Enhanced Expression of Lp-PLA2 and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic Plaques. Stroke. 2008;39:1448-1455

  22. Vickers KC, Maguire CT, Wolfert R. et al. Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis. J Lipid Res. 2009 Sep;50(9):1735-43

  23. Charniot JC, Khani-Bittar R, Albertini JP et al. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments. Int J Cardiol. 2012 Oct 23. pii: S0167-5273

  24. Lind L., Simon T., Johansson L., et al. Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality. Eur Heart J. 2012 Dec;33(23):2946-54

  25. Furberg CD, Nelson JJ, Solomon C. et al. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study. J Am Geriatr Soc. 2008 May;56(5):792-9

  26. Shah P.K. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003;41:15S–22S

  27. Stary H.C., Chandler A.B., Dinsmore R.E., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355–1374

  28. Calabro P., Willerson J.T., Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003;108:1930

  29. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039 –1051

  30. Burke A.P., Tracy R.P., Kolodgie F., Malcom G.T., et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002;105:2019 –2023

  31. Verma S., Devaraj S., Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. 2006;113:2135–2150

  32. Pepys M.B., Hawkins P.N., Kahan M.C., et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res. 2005;97:e97– e103

  33. Danesh J., Whincup P., Walker M., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Brit Med J. 2000;321:199–204

  34. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1397

  35. Boekholdt S.M., Hack C.E., Sandhu M.S., et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: The EPIC-Norfolk prospective population study 1993–2003. Atherosclerosis. 2006;187:415– 422

  36. Cushman M., Arnold A.M., Psaty B.M., et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation. 2005;112:25–31

  37. Rattazzi M., Puato M., Faggin E., et al. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens. 2003;21:1787–1803

  38. Huber S.A., Sakkinen P., Conze D., et al. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999;19:2364 –2367

  39. Kerr R., Stirling D., Ludlam C.A. Interleukin 6 and haemostasis. Br J Haematol. 2001;115:3–12

  40. Seino Y., Ikeda U., Ikeda M., et al. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine. 1994;6:87–91

  41. Rus H.G., Vlaicu R., Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 1996;127:263–271

  42. Schieffer B., Schieffer E., Hilfiker-Kleiner D., et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000;101:1372–1378

  43. Schieffer B., Selle T., Hilfiker A., et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 2004;110:3493–3500

  44. Maier W., Altwegg L.A., Corti R., et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation. 2005;111:1355–1361

  45. Biasucci L.M., Liuzzo G., Fantuzzi G., et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;99:2079 –2084

  46. Lindmark E., Diderholm E., Wallentin L., Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. J Am Med Assoc. 2001;286:2107–2113

  47. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767–1772

  48. Pradhan A.D., Manson J.E., Rossouw J.E., et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. J Am Med Assoc. 2002;288:980 –987

  49. American Heart Association. Heart Disease and Stroke Statistics — 2005. Dallas, Tex: American Heart Association; 2005

  50. Peyser P.A., Bielak L.F., Chu J.S., et al. Heritability of coronary artery calcium quantity measured by electron beam computed tomography in asymptomatic adults. Circulation. 2002; 106:304-308

  51. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published correction appears in N Engl J Med. 1997; 337:356]. N Engl J Med. 1997; 336:973-979

  52. Asano K., Okamoto S., Fukunaga K., et al. Cellular source(s) of plateletactivating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun. 1999; 261:511-514

  53. Quinn M.T., Parthasarathy S., Steinberg D.. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1988; 85:2805-2809

  54. Yamada Y., Ichihara S., Fujimura T., et al. Identification of the G994→T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism. 1998;47:177-181

  55. Yamada Y., Yoshida H., Ichihara S., et al. Correlations between plasma platelet-activating factor acetylhydrolase (PAFAH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis. 2000; 150:209-216

  56. Yamamoto I., Fujitsu J., Nohnen S., et al. Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2003; 59:219-224

  57. Tselepis A.D., Chapman J.M.. Inf lammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002; 3(4):57-68

  58. Tsaoussis V., Vakirtzi-Lemonias C.. The mouse plasma PAF acetylhydrolase, II: it consists of two enzymes both associated with the HDL. J Lipid Mediat Cell Signal. 1994; 9:317-331

  59. Boekholdt S.M., T. Keller T., Wareham N.J., et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 2005;25(4): 839-46

  60. Hakkinen T., Luoma J.S., Hiltunen M.O., et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999; 19:2909-2917

  61. Singh U., Zhong S., Xiong M., et al. Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice. Clin Sci (Lond). 2004; 106:421-432

  62. Memon R.A., Fuller J., Moser A.H., et al. In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. Am J Physiol. 1999; 277(1,pt 2):R94-R103

  63. Shannon G.Y., Dunlay D., Jaffe A.S., et al. Plasma lipoprotein-associated phospholipase A2 levels in heart failure: Association with mortality in the community. Atherosclerosis. 2008; 07.035

  64. Brilakis E.S., Khera A., Saeed B., et al. Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Coronary and Aortic Atherosclerosis: Findings from the Dallas Heart Study. Clin Chem. 2008; 54(12):1975-81

  65. Daniels L.B., Laughlin G.A., Sarno M.J., et al. Lipoprotein-Associated Phospholipase A? Independently Predicts Incident Coronary Heart Disease (CHD) in an Apparently Healthy Older Population: The Rancho Bernardo Study. J Am Coll Cardiol. 2008; 51:913-919

  66. Raichlin E., McConnell J.P., Bae J.H., et al. Lipoprotein-Associated Phospholipase A2 Predicts Progression of Cardiac Allograft Vasculopathy and increased Risk of Cardiovascular Events in Heart Transplant Patients. Transplantation 2008; 85(7):963-968

  67. Robins S.J., Collins D., Nelson J.J., et al. Cardiovascular Events With Increased Lipoprotein-Associated Phospholipase A2 and Low High-Density Lipoprotein-Choiesterol. The Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vase В/о/. 2008; 28(6):1172-1178

  68. Wassertheil-Smoller S., Kooperberg C., McGinn A.P., et al. Lipoprotein-Associated Phospholipase A2, Hormone Use, and the Risk of Ischemic Stroke in Postmenopausai Women. Hypertension. 2008; 51(4):1115-1122

  69. Persson M., Berglund G., Nelson J.J., et al. Лп-ФЛА2 Activity and Mass are Associated with Increased Incidence of Ischemic Stroke. A Population-Based Cohort Study from Malmo, Sweden. Atherosclerosis. 2008; 200(1):191-8

  70. Kiechl S., Willeit J., Mayr M., et al. Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A3 Activity, and 10-year Cardiovascular Outcomes: Prospective Results from the Bruneck Study. Arterioscier Thromb Vase Biol 2007; 27(8):1788-1795

  71. Mockel M., Muller R. Lipoprotein-Associated Phospholipase A2 for Early Risk Stratification in Patients with Suspected Acute Coronary Syndrome: A Multi-Marker Approach: The North Wuerttemberg and Berlin Infarction Study-ll (NOBIS-II). Clin Res Cardiol. 2007; 96(9):604-612

  72. Garza С.А., Montori V.M., Mcconnell J.P. Association Between Lipoprotein-Associated Phospholipase A2 and Cardiovascular Disease: A Systematic Review. Mayo Clin Proc. February 2007; 82(2):159-165

  73. Angelantonio E.D., Gao P., Pennells L. et al. Lipid-Related Markers and Cardiovascular Disease Prediction. JAMA, 2012—Vol 307, No. 23, p. 2499-2506

  74. Khot U.N., M Khot.B., C Bajzer.T., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290(7):898-904

  75. Castelli W.P. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996; 124 Suppl:S1-9

  76. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Москва, 2012 г

  77. Helfand М., et al. C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force Annals of Internal Medicine, 2009, October

  78. BraunL.T., DavidsonM.H. Lp-PLA2: A new target for statin therapy. Curr Atheroscler Rep. 2010 Jan; 12(1):29-33

  79. Wang Z.H., X Liu L, Zhong M., et al. Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. J Clin Pharmacol. 2010 Mar; 50(3):311-9. Epub 2009 Oct 6

  80. KaralisI.K., Bergheanu S.C., Wolterbeek R., et al. Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. JCurr Med Res Opin. 2010 Oct;26(10):2301-13

  81. Racherla S., Arora R. Utility of Lp-PLA2in Lipid-Lowering Therapy. Am J Ther. 2010 Jul 10

  82. QiaoZ., Ren J., ChenH. Simvastatin reduces expression and activity of lipoprotein-associated phospholipase A(2) in the aorta of hypercholesterolaemic atherosclerotic rabbits. J Int Med Res. 2009 Jul-Aug; 37(4):1029-37

  83. White H., Held C., Stewart R., et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J. 2010 Oct; 160(4):655-61

  84. The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (SOLID-TIMI 52)

  85. Hatoum IJ, Nelson JJ, Cook NR. et al. Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr. 2010 Mar;91(3):786-93

  86. Kaminsky LA, Ozemek C. Clin Biochem. 2012 Jun;45(9):700-2. Diurnal variation in lipoprotein-associated phospholipase A(2) (Lp-PLA(2))

  87. Bekci TT, Kayrak M, Kiyici A. et al. The relation between Lp-PLA2 levels with periodic limb movements. Sleep Breath. 2012 Mar;16(1):117-22

  88. Basu A, Jensen MD, McCann F. et al. Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes. Endocr Pract. 2007 Mar-Apr;13(2):147-52

  89. Iwase M, Sonoki K, Sasaki N et al. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis. 2008 Feb;196(2):931-6

  90. Noto H, Chitkara P, Raskin P. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. J Diabetes Complications. 2006 Nov-Dec;20(6):343-8

  91. Hatoum IJ, Hu FB, Nelson JJ, Rimm EB. Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes. Diabetes. 2010 May;59(5):1239-43

  92. Ostadal P., Vondrakova D., Kruger A., et al. Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers. Lipids Health Dis. 2012 Nov 10;11:153

  93. Titov V.N., Urazalina C.Zh., Ameliushkina V.A., et al. Lipoprotein-associated phospholipase A2 in subjects at low and moderate risk estimated by the SCORE scale. Klin Med (Mosk). 2012;90(7):37-42

  94. Lanman RB, Wolfert RL, Fleming JK. et al. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol. 2006 Summer;9(3):138-43

  95. Constantinides A., de Vries R., van Leeuwen J.J., et al. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity. Eur J Intern Med. 2012 Oct;23(7):633-8

  96. Ridker P.M., MacFadyen J.G., Wolfert R.L., Koenig W. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial. Clin Chem. 2012 May;58(5):877-86

  97. Stein E.A. Lipoprotein-associated phospholipase A₂ measurements: mass, activity, but little productivity. Clin Chem. 2012 May;58(5):814-7

  98. Charniot J.C., Khani-Bittar R., Albertini J.P., et al. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments. Int J Cardiol. 2012 Oct 23. pii: S0167-5273(12)01160-6

  99. Ryu S.K., Mallat Z., Benessiano J., et al. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation. 2012 Feb 14;125(6):757-66

  100. Nelson T.L., Biggs M.L., Kizer J.R., et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study. J Clin Endocrinol Metab. 2012 May;97(5):1695-701

  101. Kizer J.R., Umans J.G., Zhu J., et al. Lipoprotein-associated phospholipase A(2) mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the Strong Heart Study. Diabetes Care. 2012 Apr;35(4):840-7

  102. Wierzbicki A.S. New directions in cardiovascular risk assessment: the role of secondary risk stratification markers. Int J Clin Pract. 2012 Jul;66(7):622-30

  103. Catapano A., Reiner Z., de Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias. The Task Force on the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011

  104. Sarlon-Bartoli G., Boudes A., Buffat C., et al. Circulating lipoprotein-associated phospholipase A2 in high-grade carotid stenosis: a new biomarker for predicting unstable plaque. Eur J Vasc Endovasc Surg. 2012 Feb;43(2):154-9

  105. Vickers K.C., Maguire C.T., Wolfert R., et al. Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis. J Lipid Res. 2009 Sep;50(9):1735-43

  106. Epps K.C., Wilensky R.L. Lp-PLA₂- a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med. 2011 Jan;269(1):94-106

  107. Kardys I., Oei H.H., van der Meer I.M., et al. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):631-6

  108. Dohi T., Miyauchi K., Okazaki S., et al. Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome. Atherosclerosis. 2011 Dec;219(2):907-12


Каталог: files -> autoref
autoref -> Диссертация на соискание ученой степени доктора медицинских наук Научные консультанты: академик рамн с. К. Терновой
autoref -> Факторы риска аортокоронарного шунтирования у больных ранней постинфарктной стенокардией
autoref -> «Факторы коронарного ангиогенеза и влияние на них различных методов лечения у больных ишемической болезнью сердца» 14. 01. 05 кардиология
autoref -> Обоснование комбинированной терапии акне у женщин с учетом патогенетических особенностей заболевания 14. 01. 10 кожные и венерические болезни
autoref -> Нии кардиологии им. А. Л. Мясникова фгбу ркнпк мз РФ
autoref -> Влияние ингаляционного оксида азота и небиволола на клинико-гемодинамический и нейро-гуморальный статус больных с легочной гипертензией различной этиологии
autoref -> Профилактика инфекций, передаваемых половым путем, среди несовершеннолетних посредством повышения их информированности 14. 01. 10 кожные и венерические болезни
autoref -> Системные проявления воспалительной реакции при коронарном стентировании: прогностическая значимость и возможности для фармакологического воздействия

Скачать 1.22 Mb.

Поделитесь с Вашими друзьями:
1   2   3   4   5



©zodomed.ru 2024
    Главная страница
Автореферат
Анализ
Бизнес-план
Биография
Бюллетень
Викторина
Глава
Диплом
Дипломная работа
Диссертация
Доклад